Neil McIntosh looks at the use of 'monoclonal antibodies', rather than drugs, to treat our pets - especially those with ...
This biotech small-cap's grown its dividend by 140% since 2016! So with an 8.3% yield, is now the time to add it to my Stocks ...
Kiniksa (KNSA) shifts from survival to growth as Arcalyst nears blockbuster sales and pipeline KPL-387 readouts loom—get the ...
The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple ...
As of Friday, January 23, Coherus Oncology, Inc.’s CHRS share price has surged by 21.70%, which has investors questioning if ...
Nirsevimab may offer infants stronger protection against severe respiratory syncytial virus than maternal vaccination, ...
Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of ...
As Lindsey Vonn’s comeback run heads toward a peak with Team USA at the upcoming 2026 Winter Olympics, Invivyd is adding the ...
Objectives Understanding the molecular changes in the preclinical synovium is crucial for identifying factors that drive ...
The educational campaign will focus on teaching the American public about antibodies and preventing infectious diseaseThe collaboration will ...
In the treatment of inflammatory bowel disease, synthetic mucus gels can be used to deliver monoclonal antibodies without inducing broad immunosuppression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results